Prostate Cancer: H&E Diagnosis & Classification Overview

From specimen to diagnosis

Most prostate cancer enters the pathology laboratory as core needle biopsies — typically a set of thin tissue cylinders sampling different regions of the gland — or, after surgery, as a radical prostatectomy specimen. The pathologist's first task is deceptively simple to state and genuinely difficult to perform: decide whether small clusters of glands within an otherwise benign-looking prostate are malignant, and if so, how aggressive they appear.

The challenge is that prostate cancer often presents as tiny foci of subtly abnormal glands embedded among benign tissue, where benign mimics (atrophy, adenosis, partial atrophy) can look worrisome. The diagnosis therefore integrates three layers of information from the hematoxylin-and-eosin (H&E) slide: architecture (how glands are arranged), cytology (the appearance of individual cell nuclei), and the presence or absence of the basal cell layer [1].

That last feature is pivotal. Benign prostatic glands are lined by two cell layers — secretory (luminal) cells sitting on a continuous basal cell layer. Invasive adenocarcinoma loses the basal layer. When a focus is small or ambiguous, the pathologist confirms this on additional stains: an immunohistochemistry (IHC) triad in which basal markers (p63, HMWCK) are absent, AMACR/P504S is positive, and NKX3.1 confirms prostatic lineage [1]. This triad is the diagnostic workhorse for resolving small suspicious foci.

The H&E picture (synthesized morphology)

On H&E, conventional prostate cancer is recognized by infiltrative small glands that crowd between or around benign structures, lacking the orderly architecture of normal acini. The malignant nuclei are enlarged (nucleomegaly) and characteristically show prominent nucleoli. No single feature is diagnostic alone — the diagnosis emerges from the convergence of infiltrative growth, nuclear changes, and the absent basal layer [1].

As tumors become more aggressive, their architecture deteriorates in a stereotyped way that forms the basis of grading: discrete well-formed glands give way to fused glands, then cribriform "sieve-like" structures, and finally sheets of cells, single infiltrating cells, or areas of necrosis [2]. The evidence suggests that how the glands are arranged carries more prognostic weight than the cell-type label, which is why grading — not subtype — is the classification spine in the prostate.

The major categories

Several distinct entities are recognized in the current WHO framework [1]. Each is a candidate for its own detailed article.

• Acinar adenocarcinoma (conventional) — by far the dominant form. Defined by infiltrative small glands lacking basal cells, nucleolar prominence, and the IHC triad above. At the molecular level it shows recurrent alterations including TMPRSS2::ERG fusion (in roughly half of cases), PTEN loss, and SPOP/FOXA1 subsets [1]. For this entity, grading drives risk far more than any subtype designation.

• Intraductal carcinoma of the prostate (IDC-P) — a malignant epithelial proliferation that fills and expands pre-existing ducts and acini, forming dense cribriform or solid patterns with marked atypia. Crucially, the basal cell layer is retained (p63/HMWCK positive), distinguishing it from invasive cancer, while AMACR is positive [1]. IDC-P is almost always accompanied by high-grade invasive disease and adverse genomics (including PTEN loss and BRCA2 alterations). By convention it is not assigned a Gleason grade itself but is reported as an adverse feature.

• Cribriform pattern 4 — not a separate tumor type but an architectural pattern within acinar cancer that warrants explicit mention because it carries adverse genomics and independent prognostic significance [2]. It is reported separately even though it folds into the grade.

• Neuroendocrine / small cell carcinoma of the prostate — a high-grade entity with small-cell or large-cell neuroendocrine morphology. It expresses neuroendocrine markers (synaptophysin, chromogranin, INSM1), frequently loses AR and PSA, and often retains NKX3.1 as a lineage clue [1]. Molecularly it is characterized by RB1 and TP53 loss. Importantly, a treatment-emergent form can arise after androgen-deprivation therapy through lineage plasticity — a clinically distinct phenomenon in which adenocarcinoma "switches" toward a neuroendocrine phenotype.

How grading and staging work

In the prostate, the central classification output is the grade, derived from the Gleason architectural system and reported as an ISUP Grade Group (a 5-tier system introduced through international consensus) [2]. The patterns map as follows:

• Pattern 3 = discrete, individually recognizable glands
• Pattern 4 = fused glands, cribriform, or glomeruloid forms
• Pattern 5 = sheets, single cells, or comedonecrosis

These are combined into a score and translated to a Grade Group:

• Grade Group 1 = Gleason 6 (3+3)
• Grade Group 2 = 3+4
• Grade Group 3 = 4+3
• Grade Group 4 = Gleason 8
• Grade Group 5 = Gleason 9–10 [2]

The Grade Group is the single most important pathology number for risk stratification. Two features are reported separately because of their independent adverse weight: cribriform pattern 4 and intraductal carcinoma [2]. Staging (extent of disease — within the gland, beyond the capsule, into nodes, distant) is a separate axis layered on top of grade; the H&E report supplies the local-extent components.

Why classification matters

Because grading drives prognosis, the precision of H&E interpretation directly affects how a patient's disease is understood. A Grade Group 1 tumor and a Grade Group 5 tumor are the same "type" (acinar adenocarcinoma) but represent very different biology. Flagging IDC-P or cribriform morphology can shift a case into a higher-risk category even when the gland-counting alone might not. Identifying neuroendocrine differentiation matters because such tumors behave differently and lose the androgen-receptor biology that defines hormone-based therapy class eligibility — the molecular associations (e.g., BRCA2 in IDC-P contexts; RB1/TP53 in neuroendocrine disease) connect morphology to potential treatment-class considerations rather than to any individual recommendation.

What's current (recent reclassification)

The framework here reflects the WHO Classification of Urinary and Male Genital Tumours, 5th edition (2022) [1], which consolidates the ISUP Grade Group system as the grading spine [2]. The evidence is still moving in several areas that readers should treat as live rather than settled: the prognostic handling of cribriform pattern 4 and the reporting conventions for IDC-P continue to be refined, and the recognition of treatment-emergent neuroendocrine prostate cancer as a distinct, plasticity-driven phenotype is an actively evolving concept [1]. Grading conventions in particular should be verified against the current edition at the time of reporting.

---

References

1. WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, 5th ed. IARC, Lyon; 2022. ISBN 978-92-832-4512-4.

2. Epstein JI, et al. The 2014 ISUP Consensus Conference on Gleason Grading / Grade Groups. Am J Surg Pathol. 2016. doi:10.1097/PAS.0000000000000530.